Article Per Year (5 Year)
p-Index From 2020 - 2025
3.993
P-Index
This Author published in this journals
All Journal International Journal of Integrated Health Sciences The Indonesian Journal of Infectious Diseases Jurnal Respirologi Indonesia Journal of the Indonesian Medical Association : Majalah Kedokteran Indonesia SURABAYA PHYSICAL MEDICINE AND REHABILITATION JOURNAL Respiratory Science Narra J Malang Respiratory Journal Healthy Tadulako Journal (Jurnal Kesehatan Tadulako) Jurnal Ilmu Kesehatan Masyarakat Ophthalmologica Indonesiana Kesmas: Jurnal Kesehatan Masyarakat Nasional (National Public Health Journal)
Erlina Burhan
Departemen Pulmonologi Dan Kedokteran Respirasi Fakultas Kedokteran Universitas Indonesia
Biochemistry, Genetics & Molecular Biology Chemical Engineering, Chemistry & Bioengineering Dentistry Education Health Professions Immunology & microbiology Medicine & Pharmacology Nursing Public Health Other

Published : 26 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 26 Documents
Search

 1   2   3 
CORONAVIRUS YANG MERESAHKAN DUNIA Erlina Burhan
Majalah Kedokteran Indonesia Vol 70 No 2 (2020): Journal of the Indonesian Medical Association Majalah Kedokteran Indonesia Volum
Publisher : PENGURUS BESAR IKATAN DOKTER INDONESIA (PB IDI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.1234/jinma.v70i2.170

Abstract

Di penghujung tahun 2019, laporan pemerintah China membuat publik ibuat penasaran dan tim ahli sibuk meneliti. Tepat tanggal 31 Desember 2019, China melaporkan kejadian luar biasa, kasus pneumonia misterius yang belum diketahui penyebabnya, tepatnya di Kota Wuhan, Provinsi Hubei.1 Berdasarkan penelitian terhadap 41 pasien pertama kasus diduga terkait atau terpapar dengan satu pasar hewan di Wuhan, China.
SUCCESSFUL TREATMENT OF ENDOBRONCHIAL TUBERCULOSIS IN PERSAHABATAN NATIONAL RESPIRATORY REFERRAL HOSPITAL Sari, Adistya; Aniwidyaningsih, Wahju; Burhan, Erlina
Jurnal Respirologi Indonesia Vol 40, No 2 (2020)
Publisher : Perhimpunan Dokter Paru Indonesia (PDPI)/The Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/jri.v40i2.102

Abstract

Backgrounds: Endobronchial tuberculosis (EBTB) is a special form of respiratory tuberculosis that continues to be a health problem because bronchostenosis may develop as a serious complication despite efficacious antituberculosis chemotherapy. The EBTB has nonspesific signs and symptoms, therefor it may cause misdiagnosis and delayed diagnosis. Persahabatan National Respiratory Referral Hospital doesn?t have data about successful treatment of EBTB Methods: This was a retrospective study of EBTB patients based from the medical record and confirm with bronchoscopy data from January 2013 to December 2017. Endobronchial tuberculosis diagnosed based from microbiology, histopathology examination or based on combination of clinical symptoms, radiology and bronchoscopy lesion appearance. Endobronchial tuberculosis treatment considered successful if there is improvement in clinical symptoms, microbiological conversion, accompanied by improvement or no change in the number of lesions or the radiological appearance. Results: The study sample consisted of 30 subjects. Majority of the subjects were female (86,7%), age
The Proportion of Latent Tuberculosis Infection in Naive Lung Cancer Patients at Persahabatan Hospital Jakarta Erlina Burhan; Ririen Razika Ramdhani; Jamal Zaini
Jurnal Respirologi Indonesia Vol 39, No 4 (2019)
Publisher : Perhimpunan Dokter Paru Indonesia (PDPI)/The Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/jri.v39i4.73

Abstract

Background: Lung cancer and pulmonary tuberculosis (TB) are two major public health problems associated with significant morbidities and mortalities. The increased prevalence of active TB and latent TB reactivation in lung cancer patients and negative effect of pulmonary TB in lung cancer prognosis needed screening of lung cancer patients for latent TB infection (LTBI). This study aimed to determine the proportion of LTBI in lung cancer patients, their characteristics and the relationship between them. Methods: This study used cross-sectional design. Collecting sample used consecutive sampling of 86 newly diagnosed treatment-naive lung cancer patients from RSUP Persahabatan in 2015 to 2016. The presence of LTBI was determined by Quantiferon-TB Gold-In-Tube (QFT- GIT) after having Mycobacterium TB not detected result from Xpert MTB/RIF sputum test. Demographic characteristics and cancer-related factors associated with LTBI were investigated. Results: The results of latent TB tests were IGRA(+) 12.8%, IGRA(-) 68.6% and IGRA(I) 18.6%. Number of male patients with lung cancer with latent were 68.6%, as many as 55.8% were immunized with BCG, 4.6% had close contact with TB and 64% were using smoking. Most types of cancer were adenocarcinomas (77.9%) with advanced stage (82.6%) and general display status 2 (50%). The characteristics that show an association with IGRA results are the location of the cancer and the total lymphocyte count. Conclusion: The proportion of latent TB in lung cancer patients at the RSUP Persahabatan was 12.8%. The location of the cancer associated with the area of typical TB was related to latent TB, although it cannot be canceled. Results of IGRA(I) in lung cancer patients with low total lymphocyte counts prove IGRA sensitivity in the protection of latent TB infection in immunocompromised patients. (J Respir Indo. 2019; 39(4): 256-65)
Corona Virus Disease 2019 Diah Handayani; Dwi Rendra Hadi; Fathiyah Isbaniah; Erlina Burhan; Heidy Agustin
Jurnal Respirologi Indonesia Vol 40, No 2 (2020)
Publisher : Perhimpunan Dokter Paru Indonesia (PDPI)/The Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/jri.v40i2.101

Abstract

Corona virus disease 2019 (COVID-19) is a new name given by World Health Organization (WHO) of 2019 novel corona virus infection, reported at the end of 2019 from Wuhan, Cina. The spread of infection occurs rapidly and creates a new pandemic threat. Etiology of COVID-19 was identified in 10 January 2020, a betacorona virus, similar with severe acute respiratory syndrome (SARS) and middle east respiratory syndrome (MERS CoV). The clue diagnosis pathway of COVID-19 were history of travel from Wuhan or others infected countries within 14 days prior, and symptoms of acute respiratory illness (ARI) or lower respiratory infection (pneumonia) with the result of real time polymerase chain reaction (RT-PCR) specific for COVID-19. The WHO classified COVID-19 into suspect case, probable case and confirmed case. Indonesia Ministry of Health classified the case into in monitoring (ODP), patient under surveillance (PDP), people without symptom (OTG) and confirmed case. Specimens for detection COVID-19 could be acquired from nasal and nasopharynx swab, sputum and another lower respiratory aspirate including broncoalveolar lavage (BAL). Management of COVID-19 consist of isolation and infection control, supportive treatment according to the disease severity which could be mild (acute respiratory infection) to severe pneumonia or acute respiratory distress syndrome (ARDS). Disease transmission is via droplets and contact with droplets. Currently, there is no antiviral and vaccine. Prevention is very important for this disease by limitation of transmission, identification and isolate patients. Prognosis is determined by severity of the disease and patient comorbidity. Information about this novel disease remains very few, studies are still ongoing and is needing further research to fight with this new virus. (J Respir Indo. 2020; 40(2): 120-30)
Type 2 Diabetes Mellitus And Hemoptisis Risk Factor In Lung Tuberculosis : A Case Control Study Widhy Yudistira Nalapraya; Jaka Pradipta; Muhammad Ikhsan Mokoagow; Erlina Burhan
Jurnal Respirologi Indonesia Vol 40, No 3 (2020)
Publisher : Perhimpunan Dokter Paru Indonesia (PDPI)/The Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/jri.v40i3.111

Abstract

Background: Diabetes mellitus (DM) is a risk factor for tuberculosis (TB) morbidity and mortality. Increasing cases of type 2 DM in the world increases the risk of developing TB. The frequency of DM in TB patients was reported to be around 10-15% and the prevalence of this infectious disease was 2-5 times higher in diabetic patients compared to non-diabetics. Hemoptysis is a respiratory symptom which can be life threatening. Tuberculosis and bronchiectasis are the two most common ethology of hemoptysis, while TB with DM are the cause of recurrent hemoptysis. Methods: This was case control study which used the medical records data of diabetic patients infected with TB who experienced hemoptysis and no hemoptysis, treated at Fatmawati General Hospital during 2017. Sampling method was total sampling. Results: There were 12 hemoptysis patients with DM comorbidity and 31 patients without DM comorbidity. As many as 58% of patients with DM had new cases of pulmonary TB and 42% had history of treatment completion. The correlation between hemoptysis of TB patients with DM compared to without DM obtained a relative risk of 1.535 (95% CI=0.677-2.618) Conclusion: The proportion of hemoptysis in TB patients with DM comorbidity was 10.3%. Diabetes Mellitus was a risk factor for hemoptysis 1.535 times higher compared to TB patients without DM but statistically not significant. (J Respir Indo. 2020; 40(3): 144-9)
Pulmonary Mycoses in Indonesia: Current Situations and Future Challenges Anna Rozaliyani; Anwar Jusuf; Priyanti ZS; Erlina Burhan; Diah Handayani; Henie Widowati; Satria Pratama; Findra Setianingrum
Jurnal Respirologi Indonesia Vol 39, No 3 (2019)
Publisher : Perhimpunan Dokter Paru Indonesia (PDPI)/The Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (900.239 KB) | DOI: 10.36497/jri.v39i3.69

Abstract

Cases of pulmonary mycosis or pulmonary fungal diseases continues to increase in frequency along with the expanding population with impaired immune systems, including patients with pre-existing pulmonary diseases. Changing profile of underlying diseases might cause altering diseases profile as well. In previous decades, Pneumocystis pneumonia was the most common pulmonary mycosis in HIV-infected patients. As the increasing number of TB cases, pulmonary malignancy, chronic obstructive pulmonary disease (COPD) and certain chronic diseases, other pulmonary mycoses also increase such as chronic pulmonary aspergillosis, cryptococcosis, histoplasmosis, and other filamentous fungal infection. Furthermore, the airborne fungal particles of Aspergillus and other fungi could seriously worsen asthma or allergic respiratory diseases. In low- and middle-income countries, including Indonesia, lack of diagnostic facilities may lead to inadequate treatment. It will contribute to poor clinical outcomes with high mortality rates. The awareness among clinicians and other health workers of this epidemiology changes is the important step in early diagnosis and better managemenet of pulmonary mycosis in the future. (J Respir Indo. 2019; 39(3): 210-4)
Inflammatory Markers upon Admission as Predictors of Outcome in COVID-19 Patients Budhi Antariksa; Erlina Burhan; Agus Dwi Susanto; Mohamad Fahmi Alatas; Feni Fitriani Taufik; Dewi Yennita Sari; Dicky Soehardiman; Andika Chandra Putra; Erlang Samoedro; Ibrahim Nur Insan Putra Darmawan; Hera Afidjati; Muhammad Alkaff; Rita Rogayah
Jurnal Respirologi Indonesia Vol 41, No 4 (2021)
Publisher : Perhimpunan Dokter Paru Indonesia (PDPI)/The Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/jri.v41i4.185

Abstract

Background: Coronavirus disease 2019 (COVID-19) may cause dysregulation of the immune system, leading to hyperinflammation. Inflammatory markers can be used to predict in-hospital mortality in COVID-19 patients. This research was aimed to investigate the association between the levels of various inflammatory markers and mortality in COVID-19 patients.Methods: This study was conducted at Persahabatan National Respiratory Referral Hospital, Indonesia. Blood tests were performed upon admission, measuring the C-reactive protein, PCT, leukocyte, differential counts, and platelet count. The outcome measured was the mortality of hospitalized COVID-19 patients. Statistical analysis methods included the Mann–Whitney U test, receiver operating characteristic (ROC) analysis, and area under the curve (AUC) test.Results: Total 110 patients were included, and the laboratory values were analyzed to compare survivors and non-survivors. The non-survivor group had significantly higher leukocyte count, lower lymphocyte count, higher CRP and PCT levels, higher neutrophil-to-lymphocyte ratio (NLR), higher platelet-to-lymphocyte ratio (PLR), and lower lymphocyte-to-CRP ratio. As predictors of mortality, AUC analysis revealed that PCT, CRP, NLR, and PLR had AUCs of 0.867, 0.82, 0.791, and 0.746, respectively.Conclusions: Routine and affordable inflammatory markers tested on admission may be useful as predictors of in-hospital mortality in COVID-19 patients requiring hospitalization.
PERANAN PROKALSITONIN PADA PNEUMONIA KOMUNITAS Mirza Purwitasari; Erlina Burhan; Priyanti Z. Soepandi
The Indonesian Journal of Infectious Diseases Vol 2, No 2 (2015): THE INDONESIAN JOURNAL OF INFECTIOUS DISEASES
Publisher : Rumah Sakit Penyakit Infeksi Prof Dr. Sulianti Saroso

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (245.482 KB) | DOI: 10.32667/ijid.v2i2.25

Abstract

Abstrak : Keterbatasan dalam mendiagnosis infeksi respirasi dari klinis, gejala penyakit dan pemeriksaan mikrobiologis, keberadaan biomarker dapat dijadikan informasi tambahan dalam meningkatkan diagnosis dan prognosis yang membantu dalam keputusan pemberian terapi. Penggunaan prokalsitonin dapat membantu diagnosis membedakan dari infeksi yang disebabkan oleh virus, menilai derajat risiko pasien dan keputusan pemberian, penghentian dan durasi antibiotik yang optimal. Pneumonia komunitas masih menjadi masalah kesehatan. Prokalsitonin pada akhir-akhir ini menjadi perhatian prognosis pada pneumonia komunitas. , baik yang diakibatkan oleh bakter iatau pun bukan. Prokalsitonin juga mempunyai kemampuan yang lebih baik dari pada C-reaktif protein sebagai biomarker petanda inflamasi dan mempunyai hubungan yang signifikan dengan skor sistem yang menilai klinis dan angka kematian. Kata kunci: Pneumonia komunitas, prokalsitoninAbstract : In light of the limitations of clinical signs and symptoms and traditional microbiologic diagnostic for respiratory infections, blood biomarkers that correlate with the presence and extent of bacterial infections may provide additional useful information to improve diagnostic and prognostic efforts and help with therapeutic decisions in individual patients. A growing body of evidence support the use of procalcitonin (PCT) to differentiate bacterial from viral respiratory diagnoses, to help risk stratify patients, and to guide antibiotic therapy decisions about initial need for, and optimal duration of, therapy.Communityacquired peneumonia (CAP) is a significant clinical and public health problem. Recently, attention has been paid to the potential for procalcitonin (PCT) both to differentiate the diagnosis and to indicate the prognosis of pneumonia. Procalsitonin has the ability to supplement clinical information to determine whether or not the cause of the inection is likely to be bacterial. In addition, PCT seems to be superior to the most prevalent inflammatory biomarker C-reactive protein a
Long COVID: Diagnosis and Treatment of Respiratory Syndrome in Post COVID-19 Conditions Erlina Burhan
Jurnal Respirologi Indonesia Vol 42, No 3 (2022)
Publisher : Perhimpunan Dokter Paru Indonesia (PDPI)/The Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/jri.v40i3.279

Abstract

The ongoing COVID-19 pandemic has given rise to another medical burden that came from the symptoms experienced by patients after acute infection with SARS-CoV-2, a condition often called as Long COVID. As the number of COVID-19 cases remain rising, various studies and scientific researches are being conducted to understand more about Long COVID, and findings have consistently shown increased burden due to Long COVID that needs more attention from the clinical world. This article review collects various sources regarding the diagnosis and management of respiratory syndrome in post-COVID-19 conditions. Long COVID, currently referred to as a post-COVID-19 condition, consists of symptom(s) that occurs in individuals with a history of probable or confirmed SARS-CoV-2 infection, with symptoms lasting at least two months and cannot be explained by any alternative diagnosis. Symptoms that occur are very diverse from various organ systems, including the respiratory system. Knowledge regarding the possible symptoms as well as a thorough evaluation is needed to identify and diagnose post-COVID-19 conditions, and multidisciplinary management through a tiered system may help reach more cases of post-COVID-19 conditions. The treatment for post-COVID-19 conditions needs to be adjusted to the patient's condition, and the administration of pharmacological therapy such as steroids, bronchodilators, and mucolytics/antioxidants has to be based on clinical symptoms and radiological abnormalities.
Mesenchymal Stem Cells Role in COVID-19 Myocardial Injury Triya Damayanti; Mega Juliana; Yasmina Hanifah; Erlina Burhan; Putri Suci Ramadhany
Jurnal Respirologi Indonesia Vol 42, No 4 (2022)
Publisher : Perhimpunan Dokter Paru Indonesia (PDPI)/The Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/jri.v42i4.192

Abstract

Coronavirus Disease-19 (COVID-19) has become a global pandemic that affected the lives of billion individuals. The clinical spectrum of the disease varies from asymptomatic form to severe manifestation in term of acute respiratory distress syndrome (ARDS), shock and septic shock and multiple organ dysfunction syndrome (MODS). Clinical studies have also reported an association between COVID-19 and cardiovascular manifestation, such as myocardial injury, arrhythmias, acute coronary syndrome (ACS) and thromboembolism. Myocardial injury has been reported frequently and is associated with high mortality. The currently approved strategies for COVID-19 are supportive rather than curative treatment. Cell-based approaches, primarily using mesenchymal stem cell (MSC) has demonstrated safety and possible efficacy as an adjuvant therapy in COVID-19 patient. Mesenchymal stem cells have shown important role in the therapy of cardiovascular disease due to their prominent features including their ability to differentiate into cardiovascular cells, immunomodulatory properties, antifibrotic activity and ability to undergo neovasculogenic.
Co-Authors - Afrizal A. M. Jayusman Adang Bachtiar Adyasiwi, Galoeh Afladhia, Hanna L. Agus Dwi Susanto Agustin, Heidi Agustin, Heidy Akbar, Fadhian Andini, Salsabila R. Aniwidyaningsih, Wahju Anna Rozaliyani Anwar Jusuf Anwar Jusuf Arfan, Ahmad Aria Kekalih Arief Riadi Arifin Arifin Nawas Arifin Nawas Arifin, Arief Riadi Aristyo, Kevin Ary Indriana Savitri Asri C. Adisasmita Aufa, Akhdan Azzumar, Farchan Bahri, Syukrini Bahtiar Husain Bambang Dwi Hasto Baskoro, Hario Budhi Antariksa Budi Haryanto Budi Prasetyo Budi Prasetyo Budiman Bintang Prakoso Dahlan, Muhammad Sopiyudin Dewi Yennita Sari Diah Handayani Diah Handayani Dwi Rendra Hadi Eddy Suratman Elisna Syahruddin Elsye Souvriyanti, Elsye Erlina, Andi Fasli Jalal Felim, Ris Raihan Ferian, Muhammad Farel Findra Setianingrum Firdawati, Firdawati Gusnanto, Arief Gustya, Gita Fajri Hario Baskoro Hasibuan, Thariq Emyl Taufik Hasto, Bambang Dwi Henie Widowati Hera Afidjati Husain, Bahtiar Ibrahim Nur Insan Putra Darmawan Ilham, Ahmad F. Ilham, Ahmad Fadhil Indra Kusuma Isbaniah, Fathiyah Jaka Pradipta Jendrius Jendrius Kartikawati, Falah Kurniawan, Gerry Mega Juliana Mega Juliana Menaldi Rasmin Mirza Purwitasari Mohamad Fahmi Alatas Muchtiar, Mulyadi Muhamad Sidik Muhammad Alkaff Muhammad Ikhsan Mokoagow MUHAMMAD TAUFIK Nalapraya , Widhy Yudistira Noorwati Sutandyo Nugraha, Darrin Ananda Pangestu, Hendri Priyanti Z. Soepandi Priyanti ZS Putra, Andika Chandra Putri Suci Ramadhany Rahardjo, Tri Apriliawan Bendarto Rahmad Gurusinga Rakasiwi, Muhammad ID. Rakasiwi, Muhammad Ilham Dhiya Rifqatussaadah, Rifqatussaadah Rika Bur Rika Yuliwulandari, Rika Rima Semiarty Ririen Razika Ramdhani Rita Rogayah Rizanda Machmud Samoedro, Erlang Saputra, Tetra Arya Sari, Adistya Sariasih Arumdati Satria Pratama Satria Pratama Satria Pratama Savitri, Ary Indriana Soehardiman, Dicky Syntia Nusanti Taufik, Feni Fitriani Tika Dwi Tama Tjandra Yoga Aditama Triya Damayanti Triya Damayanti Tugas Ratmono Tugas Ratmono, Tugas Utomo, Ahmad Rusdan H Wandawa, Azlina D Wardoyo, Muhammad Prasetio Widjanantie, Siti Chandra Yasmina Hanifah Yasmina Hanifah Yulia Suciati Zaini, Jamal